ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MBRK Middlebrook Pharmaceuticals (MM)

0.1335
0.00 (0.00%)
31 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Middlebrook Pharmaceuticals (MM) NASDAQ:MBRK NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1335 0 01:00:00

MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Second Quarter 2009 Financial and Operational Results

14/07/2009 1:13pm

Business Wire


Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart


From Aug 2019 to Aug 2024

Click Here for more Middlebrook Pharmaceuticals (MM) Charts.

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is scheduled to announce its financial results for the 2009 second quarter on Thursday, August 6, 2009, before the market opens. At 9:00 a.m. (ET) on that day, MiddleBrook management will conduct a conference call to review results for the 2009 second quarter.

To listen live to the call, dial 1-800-813-8504 or 1-660-422-4526. A replay of the call will be available starting at approximately 11 a.m. on August 6 through 5 p.m. on August 13, 2009. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291, and enter the conference ID #19864871.

A live audio webcast of the conference call also will be available by going to the Investor Relations section of MiddleBrook's web site, www.middlebrookpharma.com. A replay of the webcast will be available starting at approximately 11 a.m. on August 7 through 5 p.m. on Sept. 4, 2009.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. The Company has developed a proprietary delivery technology called PULSYS®, which enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MiddleBrook is currently developing a portfolio of anti-infective PULSYS products. The Company’s near-term corporate strategy is to improve dosing regimens and/or reduce frequency of dosing which it believes will result in improved patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX, the immediate-release brand of cephalexin, and MOXATAG – the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

1 Year Middlebrook Pharmaceuticals (MM) Chart

1 Year Middlebrook Pharmaceuticals (MM) Chart

1 Month Middlebrook Pharmaceuticals (MM) Chart

1 Month Middlebrook Pharmaceuticals (MM) Chart

Your Recent History

Delayed Upgrade Clock